Regulated health-science innovation, integrated into the cannabis platform.
BloomBridge Pharma is embedded in integrative technology and science — connecting decades of cultivation heritage with medical research, clinical advisory relationships, genetic IP, and pharmaceutical-grade production protocols. Activity is conducted only where supported by source material, licensed counterparties, and applicable approvals.
Evidence-based, regulator-engaged.
Rooted in decades-long research, development, and innovation, BloomBridge Pharma is embedded in integrative technology and science. The Group maintains advisory and developmental relationships across medical cannabis, psychedelic-assisted therapy research, oncology cannabinoid research, and pediatric neurology — supporting clinical collaborations where regulatory frameworks allow.
Over the last operating cycle, the Group has extended into adjacent regulated markets where the same disciplines — licensing, provenance, compliance, and counterparty work — directly transfer. The health-science division connects BloomBridge's cannabis heritage with regulated pharma and health-science opportunities, clinical advisory relationships, genetic IP, evidence-based cannabis research, and compliance-grade documentation.
Therapeutic and research domains.
Medical cannabis
Pharmaceutical-grade cannabis development against GMP-aligned SOPs, drawing on 30+ years of cultivar IP, reproducible standardized protocols, and evidence-based product design.
Oncology cannabinoid research
Advisory relationships with leading cancer-cannabinoid research laboratories, including programmes advancing standardized therapeutic protocols and the bioactive applications of cannabis compounds.
Pediatric neurology
Clinical-trial design and study oversight in epilepsy and neurodevelopmental conditions, under specialist pediatric-neurology supervision.
Psychedelic-assisted therapy research
Strategy and trial-design alignment under the Group's Chair of Research, in coordination with MAPS-affiliated regulated medical research of psychedelics and cannabis.
Genetic IP & extractions
Cultivar development, selection, stabilization, terpene research, cannabinoid profiling, and concentrate systems under the Group's chief genetics and extractions office.
Regenerative & precision therapeutics
Advisory across biomaterials and translational research, and gene-editing applications including CRISPR-based cancer research.
Operating platforms within the division.
How the division connects to the Group.
BloomBridge Pharma sits between Cali Organics' cultivation heritage and BloomBridge Digital's audit-ready infrastructure. Genetic IP and standardized protocols flow from the cannabis division into clinical research and product development. Provenance, batch records, and study documentation are recorded on the Group's ledger platforms. The Medical & Research Board reviews counterparty-facing documentation across the cannabis vertical, ensuring evidence-based framing is preserved end to end.
Counterparty access to BloomBridge Pharma.
Research collaboration packets, Medical & Research Board profiles, GMP-protocol documentation, and clinical engagement frameworks issued upon request under NDA.